Andrej Dukát, Zbigniew Gaciong, Piotr Abramczyk
In the year 2007 the international study NICS was performed in two neighbor European countries (Poland and Slovakia) that followed patients at risk with metabolic syndrome with the identical protocol. Later on comparisons of two different populations and their clinical practice could be evaluated. This study was designed in Poland and Slovakia used the identical protocol in our own clinical practice conditions. Patients with metabolic syndrome which represents in both our countries a significant health and economical problem were included in the study group. Cardiome-tabolic sartan - telmisartan in the dose of 80 mg once daily was chosen as the evaluating study drug. Primary endpoint was to evaluate its effect on patients with hypertension in the conditions of real clinical practice with the interest on therapeutical effectiveness and chosen metabolic parameters.